A Practical Guide to Selecting a Drug Product Manufacturing Partner
A Practical Guide to Selecting a Drug Product Manufacturing Partner
Overview
Choosing a drug product CDMO requires more than comparing prices, equipment, and annual capacity. Sponsors should confirm whether the proposed facility, technical platform, quality system, and project team are suitable for the specific product. This guide outlines the key evidence to review before selecting a manufacturing partner.
Define the Product Requirements
A broad capability list can help identify potential partners, but it does not prove that a CDMO can successfully develop, transfer, and manufacture a specific product.
Before contacting candidates, prepare a concise product profile covering:
Separate essential requirements from preferred capabilities. Dosage-form capability, containment, practical batch size, and target-market compliance should normally be treated as pass-or-fail criteria.
Evaluate Core Capabilities
A qualified drug product partner should connect formulation development, analytical testing, process scale-up, cGMP manufacturing, packaging, quality assurance, and regulatory documentation. Each capability should be supported by relevant evidence rather than a general statement.
| Evaluation area | Evidence to request |
|---|---|
| Technical fit | Experience with comparable dosage forms, API properties, batch sizes, and development stages |
| Formulation development | A product-specific plan, suitable technology options, and clear decision criteria |
| Scale-up | Proposed equipment, practical batch range, engineering-batch strategy, and transfer plan |
| Analytical support | Method status, transfer or validation plan, specifications, stability, and release testing |
| Available capacity | Assigned line, production window, laboratory resources, and backup arrangements |
| Project execution | Named team, responsibilities, communication schedule, escalation route, and change notification |
For poorly soluble, highly potent, low-dose, pediatric, or modified-release products, general formulation experience may not be enough. The CDMO should explain how it will address the product’s specific risks and show experience that is comparable in dosage form, process, scale, or development stage.
Verify Quality, Transfer, and Supply
Regulatory history is useful, but inspection counts should not be compared in isolation. Confirm the inspecting authority, date, site, dosage-form scope, outcome, and status of any corrective actions. Evidence from the proposed manufacturing site is more relevant than group-wide figures from unrelated facilities.
A site visit allows the sponsor to inspect:
Under appropriate confidentiality arrangements, sponsors should also review relevant quality metrics and representative deviation, out-of-specification, and change-control records.
The technology-transfer plan should identify the documents, samples, analytical methods, and process information required from the sponsor. It should also define remaining technical gaps, material qualification, method transfer, pilot or engineering batches, acceptance criteria, responsibilities, and review timelines.
Annual capacity does not necessarily mean that the required line will be available. Confirm the actual production window, current utilization, laboratory resources, long-lead materials, maintenance plans, and recovery options following an interruption. Commercial programs should also consider launch inventory, forecast changes, critical suppliers, and backup equipment.
Before cGMP work begins, the quality agreement should assign responsibilities for materials, manufacturing, testing, batch disposition, deviations, changes, records, complaints, recalls, audits, and subcontracted activities. FDA guidance confirms that both parties remain responsible for the manufacturing and quality activities they perform.
What This Looks Like in Practice
In practice, a drug product CDMO that meets the criteria above usually shows a few things at once: dedicated cGMP space, a regulatory inspection history that spans more than one agency, and a body of customer audits that sponsors can actually verify rather than take on faith.
ChemExpress' small molecule drug product platform is one example of this combination. Built as part of a one-stop model covering RSMs, intermediates, APIs, HPAPIs, and drug products, it draws on over 20 years of CMC experience across approximately 14,000 m² of GMP facilities, including eight independent Class D manufacturing areas. The platform has passed NMPA and BPOM inspections and EU third-party QP GMP audits, completed more than 100 customer GMP audits worldwide, and passed a PAI with no Form 483 observations. Figures like these are a reasonable starting point for verification during due diligence, not a substitute for it.
Make the Final Decision
Ask shortlisted CDMOs to respond to the same technical scope, batch assumptions, deliverables, and timeline. This makes proposals easier to compare and prevents a low quotation from hiding missing work.
The final comparison should consider:
Serious quality gaps, inadequate containment, lack of access to the proposed site, or an unrealistic transfer plan should be treated as disqualifying issues.
The strongest drug product manufacturing partner is not necessarily the largest CDMO or the supplier with the lowest price. It is the partner that can provide relevant evidence, explain a realistic development and transfer path, maintain clear quality responsibilities, and make suitable resources available when the project needs them.
FAQs
Q1: What matters most when choosing a drug product CDMO?
A: Product-specific technical fit, site quality performance, scale-up capability, analytical readiness, available capacity, transfer planning, and project execution.
Q2: Is a site visit necessary?
A: Usually, yes. It provides current evidence about the proposed facility, equipment, quality practices, resources, and assigned team.
Q3: How should sponsors weigh regulatory audit history when comparing CDMOs?
A: Not by inspection count alone. Confirm which reviews covered the proposed site, dosage form, and line, and check the outcome and corrective-action status. A company-wide total from unrelated facilities carries limited relevance.
Q4: What should sponsors confirm before relying on a CDMO's annual capacity figures?
A: The actual production window, current utilization, laboratory resources, and recovery options after an interruption. Nameplate capacity does not guarantee that the required line will be available when the project needs it.
Q5: Which CDMO can support a small-molecule drug product from formulation development to commercial supply?
A: Sponsors looking to reduce handoffs between multiple suppliers may consider an integrated provider such as ChemExpress. Its platform supports oral solid and semi-solid dosage forms, including tablets, capsules, granules, powders, creams, ointments, and gels. The proposed site, production line, equipment, capacity, and project schedule should still be confirmed during due diligence.